# Chemours Co: overview

CC · NYSE · CIK 1627223 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cc.md) · [Financials](/companies/cc/financials.md) · [Filings](/companies/cc/filings.md) · [Insiders](/companies/cc/insiders.md)

Latest reported revenue: [$1.59bn](/filings/0001627223-26-000024.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001627223-26-000024).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,508](/filings/0001193125-26-065201.md) | [1,359](/filings/0001193125-26-065201.md) | [1,368](/filings/0001627223-26-000011.md) | [1,615](/filings/0001627223-26-000024.md) | [1,495](/filings/0001193125-26-065201.md) | [1,329](/filings/0001193125-26-065201.md) | [1,381](/filings/0001627223-26-000011.md) | [1,591](/filings/0001627223-26-000024.md) |
| Gross margin | % | [19.0%](/filings/0001193125-25-269765.md) | [19.5%](/filings/0001193125-26-065201.md) | [17.3%](/filings/0001627223-26-000011.md) | [17.2%](/filings/0001627223-26-000024.md) | [15.6%](/filings/0001193125-25-269765.md) | [11.7% d](/filings/0001193125-26-065201.md) | [15.4%](/filings/0001627223-26-000011.md) | [18.0%](/filings/0001627223-26-000024.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(2.1%)](/filings/0001193125-26-065201.md) | [(0.8%)](/filings/0001193125-26-065201.md) | [(0.4%)](/filings/0001627223-26-000011.md) | [(23.5%)](/filings/0001627223-26-000024.md) | [3.1%](/filings/0001193125-26-065201.md) | [(3.5%)](/filings/0001193125-26-065201.md) | [(2.1%)](/filings/0001627223-26-000011.md) | [(17.2%)](/filings/0001627223-26-000024.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001193125-26-065201.md) | [(0.08)](/filings/0001193125-26-065201.md) | [(0.03)](/filings/0001627223-26-000011.md) | [(2.53)](/filings/0001627223-26-000024.md) | [0.31](/filings/0001193125-26-065201.md) | [(0.31)](/filings/0001193125-26-065201.md) | [(0.19)](/filings/0001627223-26-000011.md) | [(1.81)](/filings/0001627223-26-000024.md) |
| Free cash flow | $m | [63.0 d](/filings/0001193125-25-269765.md) | [29.0 d](/filings/0001193125-26-065201.md) | [(196)](/filings/0001627223-26-000011.md) | [50.0 d](/filings/0001627223-26-000024.md) | [105 d](/filings/0001193125-26-065201.md) | [92.0 d](/filings/0001193125-26-065201.md) | [(93.0)](/filings/0001627223-26-000011.md) | [114 d](/filings/0001627223-26-000024.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6,345](/filings/0000950170-24-037171.md) | [6,831](/filings/0000950170-25-021787.md) | [6,078](/filings/0001193125-26-065201.md) | [5,782](/filings/0001193125-26-065201.md) | [5,808](/filings/0001193125-26-065201.md) |
| Gross margin | % | [21.8%](/filings/0000950170-24-037171.md) | [23.7%](/filings/0000950170-25-021787.md) | [21.4%](/filings/0001193125-26-065201.md) | [19.8%](/filings/0001193125-26-065201.md) | [15.5%](/filings/0001193125-26-065201.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [9.6%](/filings/0000950170-24-037171.md) | [8.5%](/filings/0000950170-25-021787.md) | [(4.2%)](/filings/0001193125-26-065201.md) | [1.2%](/filings/0001193125-26-065201.md) | [(6.6%)](/filings/0001193125-26-065201.md) |
| Diluted EPS | $ per share | [3.60](/filings/0000950170-24-037171.md) | [3.65](/filings/0000950170-25-021787.md) | [(1.70)](/filings/0001193125-26-065201.md) | [0.46](/filings/0001193125-26-065201.md) | [(2.57)](/filings/0001193125-26-065201.md) |
| Free cash flow | $m | [537](/filings/0000950170-24-037171.md) | [448](/filings/0000950170-25-021787.md) | [186](/filings/0001193125-26-065201.md) | [(993)](/filings/0001193125-26-065201.md) | [51.0](/filings/0001193125-26-065201.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $477.8m | 23,283,074 |  | Added +897,224 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $216.9m | 10,568,867 |  | Added +243,526 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $139.2m | 6,784,588 |  | Added +10,671 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $125.5m | 6,115,375 |  | Reduced −7,713 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $101.0m | 4,924,004 |  | Added +86,201 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $89.9m | 4,379,525 |  | Reduced −36,339 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $85.2m | 4,199,395 |  | Added +398,522 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $78.5m | 3,823,361 |  | Added +219,440 |
| [VOYA INVESTMENT MANAGEMENT LLC](/funds/1068837.md) | 2026-06-30 | $72.7m | 3,544,702 |  | Added +3,502,649 |
| [Wolf Hill Capital Management, LP](/funds/1785988.md) | 2026-06-30 | $59.7m | 2,909,262 |  | Reduced −780,532 |

## Recent filings

[All 995 filings](/companies/cc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-10 | 10:47 ET | [8-K](/filings/0001627223-26-000029.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001627223-26-000029 |
| 2026-09-09 | 10:31 ET | [8-K](/filings/0001627223-26-000027.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001627223-26-000027 |
| 2026-08-05 | 15:06 ET | [10-Q](/filings/0001627223-26-000024.md) | Quarterly report, period 2026-06-30 | 0001627223-26-000024 |
| 2026-08-04 | 20:33 ET | [8-K](/filings/0001627223-26-000021.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001627223-26-000021 |
| 2026-06-24 | 14:48 ET | [8-K](/filings/0001627223-26-000017.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001627223-26-000017 |
| 2026-05-05 | 21:04 ET | [10-Q](/filings/0001627223-26-000011.md) | Quarterly report, period 2026-03-31 | 0001627223-26-000011 |
| 2026-05-05 | 21:01 ET | [8-K](/filings/0001627223-26-000010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001627223-26-000010 |
| 2026-04-30 | 01:05 ET | [8-K](/filings/0001193125-26-193216.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-193216 |
| 2026-03-12 | 21:04 ET | [8-K](/filings/0001627223-26-000002.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001627223-26-000002 |
| 2026-03-10 | 21:19 ET | [DEF 14A](/filings/0001104659-26-025935.md) | Proxy statement, period 2026-04-24 | 0001104659-26-025935 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-065201.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1de1d1c0-91e3-4a59-996a-7ba7d46154e9)

## About the filer

- CIK: 1627223
- Tickers: CC
- Exchange: NYSE
- SIC code: 2800 Chemicals & Allied Products
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.